<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
TORONTO and CHICAGO, Nov. 01, 2021 (GLOBE NEWSWIRE) — Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) and medac GmbH (“medac”) today announced that the U.S. Food and Drug Administration (“FDA”) has granted a Type A meeting to medac for treosulfan, a bifunctional alkylating agent developed for use as part of a conditioning treatment for patients prior to undergoing allogeneic hematopoietic stem cell transplantation. The Type A Meeting has been scheduled to occur on November 23, 2021.
...read full article on GlobeNewsWire
